The American Society of Clinical Oncology (ASCO) and ASCO's Conquer Cancer Foundation proudly recognize the winners of ASCO's Special Awards, the Society's highest honors, and Conquer Cancer's Women Who Conquer Cancer Mentorship Awards. The recipients of these awards have worked to transform cancer care around the world. ASCO will recognize this year’s awardees at its 2019 Annual Meeting.
"We strongly oppose the White House budget proposal for Fiscal Year (FY) 2020, which would stall our nation’s progress against cancer and impede access to needed care for the millions of Americans dealing with cancer. The proposal would make drastic, unprecedented cuts to the U.S. Department of Health and Human Services—which houses the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the Centers for Medicare & Medicaid Services (CMS)."
SAN FRANCISCO – Nine studies exploring a variety of trends and approaches in immuno-oncology, including adaptive cell therapies, immune checkpoint inhibitors, the use of predictive biomarkers, and more, will be presented at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium. The meeting will take place February 28 – March 2 at the San Francisco Marriott Marquis in San Francisco, California.
ALEXANDRIA, Va.—The American Society of Clinical Oncology (ASCO) announced today that it is seeking applications for research grants for projects that use data from CancerLinQ Discovery®, an offering of ASCO's CancerLinQ® initiative, as a source. CancerLinQ Discovery® provides curated sets of de-identified data from cancer patients to academic researchers, government agencies, and others in the oncology community to generate practical knowledge that will improve cancer care.
ALEXANDRIA, Va. – A single-arm, phase II trial in men with PSMA-positive metastatic, castration-resistant prostate cancer (mCRPC) that progressed despite standard therapies, found that in the majority of men, the cancers were responsive to treatment with a novel, targeted radiation therapy called Lutetium-177 PSMA-617 (LuPSMA). This is the first prospective study of LuPSMA, part of a potential new class of treatments for men with metastatic prostate cancer. According to the researchers, men receiving the medication lived a median of 13.3 months after treatment, longer than the average 9-month survival time for men with this stage of disease. These findings will be presented at the upcoming 2019 Genitourinary Cancers Symposium in San Francisco, California.
ALEXANDRIA, Va. – A large, retrospective study analyzing five years of data from the Veterans Health Administration (VHA) found that African-American men with metastatic castration-resistant prostate cancer (mCRPC) who were treated with newer prostate cancer drugs abiraterone acetate (Zytiga) or enzalutamide (Xtandi) – and who had not received prior chemotherapy – lived 20% longer compared with white men who received the same treatment. These findings will be presented at the upcoming 2019 Genitourinary Cancers Symposium in San Francisco, California.
ALEXANDRIA, Va. – Results from the randomized, phase III KEYNOTE-426 clinical trial show that first-line therapy with a combination of the PD-1 targeted immunotherapy pembrolizumab (Keytruda) and the VEGF-targeted tyrosine kinase inhibitor axitinib (Inlyta) extended both overall survival and progression-free survival for patients with clear-cell metastatic renal cell carcinoma (mRCC), compared with the current standard of care, sunitinib (Sutent). Findings from this international study will be presented at the upcoming 2019 Genitourinary Cancers Symposium in San Francisco, California.
"Rates of obesity-related cancers are rising most sharply among young adults, but this study should serve as a wake-up call to all Americans – young and old alike – that obesity is linked to an increased risk of common cancers. If current trends continue, it is estimated that obesity will lead to more than 500,000 additional cases of cancer each year in the United States by 2030."
ALEXANDRIA, Va. — Over the past year, major research advances provided new treatment options for patients with rare, difficult-to-treat cancers. In recognition of these achievements, the American Society of Clinical Oncology (ASCO) names “Progress in Treating Rare Cancers” as the Advance of the Year. To continue the forward momentum, ASCO also debuts its list of Research Priorities to accelerate progress against cancer. These and additional milestones in cancer research are featured in ASCO’s annual Clinical Cancer Advances report, released today.
SAN FRANCISCO – Five noteworthy studies exploring new approaches in the treatment and management of liver, esophageal, colorectal, and colon cancers will be presented at the 2019 Gastrointestinal Cancers Symposium, taking place January 17-19, 2019 at the Moscone West Building in San Francisco, California.
ASCO congratulates Anand Shah, MD, MPH, on being named Senior Medical Advisor for Innovation at the Centers for Medicare & Medicaid Services (CMS). In his new role, Dr. Shah will lead efforts across CMS to advance medical innovation reporting directly to CMS Administrator Seema Verma.
Alexandria, VA. & Chicago – The American Society of Clinical Oncology, Inc. (ASCO) and Tempus announced today an agreement to support research sites participating in ASCO’s Targeted Agent and Profiling Utilization (TAPUR™) Study. The TAPUR Study is a prospective, non-randomized clinical trial that aims to describe the performance (both safety and efficacy) of Food and Drug Administration-approved, targeted anticancer drugs that are used for the treatment of patients who have both advanced cancer and a potentially actionable genomic alteration. Tumor profiling testing by a Clinical Laboratory Improvement Amendments of 1988 (CLIA)-certified, College of American Pathologists-accredited lab is required for patients to enroll in the study.
Statement from American Society of Clinical Oncology (ASCO) President Monica M. Bertagnolli, MD, FACS, FASCO, on the American Cancer Society Cancer Facts and Figures 2019 Report
The American Society of Clinical Oncology (ASCO) today published standards on the safe handling of hazardous drugs in the Journal of Clinical Oncology. ASCO’s standards largely endorse best practices issued by other stakeholder groups for safely handling hazardous drugs but offer alternatives in several key areas where more research is needed to identify evidence-based safety measures.
ALEXANDRIA, Va. – Advances in medicine and technology are emerging faster than ever before. To harness this momentum, the American Society of Clinical Oncology (ASCO) is convening Breakthrough: A Global Summit for Oncology Innovators – a new meeting focused on the intersection of medicine, scientific discovery, and innovations in technology. The inaugural meeting will take place October 11-13, 2019 at the Centara Grand Hotel CentralWorld in Bangkok, Thailand.